Sucampo Pharmaceuticals

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Pharmaceutical, Health, Inflammation, Amgen, Korn Ferry, Johnson & Johnson, Partnership, University, LLM, Sucampo Pharmaceuticals, Woman, MBA, Merrell Dow Pharmaceuticals Inc. v. Thompson, Doctor of Philosophy, Sale, Science, Rutgers University, Organization, Chemistry, Business administration, Nephrology, MD, Janssen Pharmaceuticals, Sangamo Therapeutics, Acceleron Pharma, Growth, Therapy, Family, Management, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors.
  • The selection process included working with Korn Ferry, a global organizational talent firm, to identify and screen multiple qualified candidates.
  • “We are thrilled to have Dr. Smith and Mr. Bailey join Aurinia’s Board of Directors.
  • Both Dr. Smith and Mr. Bailey have served on boards that have had successful outcomes, including sales, mergers, and partnerships.

Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer

Retrieved on: 
Wednesday, April 12, 2023
Niemann–Pick disease, MGH, Whitehead Institute, Alan, Sucampo Pharmaceuticals, Harvard College, MIT, Casma, Ara Parseghian, Washington University in St. Louis, Harvard Medical School, Internal medicine, Hospital, NPC, Therapy, Neurology, Muscular dystrophy, Global Genes, Pharmaceutical industry, Brigham, Cardiology

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer.
  • Dr. Ory joins Arbor from Casma Therapeutics, a Third Rock Ventures start up, where he served most recently as Chief Medical Officer, responsible for overseeing its muscular dystrophy and rare oncology programs.
  • “I am pleased to welcome Dr. Ory to our executive team, who has extensive experience in the neurology, metabolic, and rare disease space, spanning both industry and academia,” said Devyn Smith, Ph.D., CEO of Arbor.
  • As a champion of rare disease research, Dr. Ory has been honored many times for his work, including the Global Genes RARE Champion of Hope Award.

Clearside Biomedical Announces Leadership Team Update

Retrieved on: 
Monday, February 6, 2023
Texas Wesleyan University, Visual acuity, Alcon, SCS, Walden University, SAB, Drug, University of North Texas, Eye, Therapy, AMD, University, Patient, Sucampo Pharmaceuticals, Clinical trial, FDA, Senior, Maintenance, Pharming, Bausch & Lomb, Pharmaceutical industry, Biology, Epidemiology, M.B.A, Clearside, Public health

We thank Tom for his many contributions to Clearside.

Key Points: 
  • We thank Tom for his many contributions to Clearside.
  • His belief in, and dedication to demonstrating, the potential of administering therapeutics into the SCS has been outstanding.
  • We look forward to his continuing relationship with Clearside by providing ongoing advice and guidance as our Chief Medical Advisor-Retina and Chairman of our SAB.
  • “It has been a rewarding experience for me to work at Clearside as its Chief Medical Officer and Chief Development Officer, and I am proud of my time serving on the Clearside management team.

LAVA Therapeutics Announces Appointment of New Directors to the Board

Retrieved on: 
Friday, January 6, 2023
Cancer, Takeda Pharmaceutical Company, MedImmune, LAVA, Biotechnology, Drug discovery, Therapy, Drug development, Research, Knowledge, Immunotherapy, Mallinckrodt, University of Oxford, AstraZeneca, Bachelor of Science in Human Biology, Control, Louis Charles Kiener, University, Lancaster University, Sucampo Pharmaceuticals, Takeda Oncology, Sir William Dunn School of Pathology, Doctor of Philosophy, Fine chemical, Forma, Science, Pathology, Takeda

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of two new directors to its Board of Directors.

Key Points: 
  • UTRECHT, The Netherlands and PHILADELPHIA, Jan. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of two new directors to its Board of Directors.
  • Additionally, Guido Magni, M.D., Ph.D. will step down from his role on the LAVA Board.
  • Kiener and Ms. Wadlinger bring a wealth of knowledge in their respective fields along with deep expertise in biotechnology.
  • “Since joining our board in 2018, Dr. Magni has made invaluable contributions to LAVA, including lead program selection, launching our first clinical trials and seeing LAVA through a successful initial public offering.

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022
Sale, Gambling, Communication, Marketing, Mouse, Alcoholism, Fatty liver disease, Opioid use disorder, Infection, Inflammatory Bowel Diseases, Knowledge, NASH, Therapy, Patient, Weight loss, Obesity, Cancer, Research, Security (finance), Nature, General Services Administration, Addiction, Asthma, Inflammation, Administration, Maintenance, Pain, Annual report, Development, Growth, Diabetes, Corporation, Sucampo Pharmaceuticals, AUD, Adenosine, Drinking, Research and development, Pharmaceutical industry, Mallinckrodt, Indivior

CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2022.

Key Points: 
  • CHARLOTTESVILLE, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (Adial or the Company) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2022.
  • Overall, we have made significant strides during the third quarter and look forward to providing further updates as developments unfold.
  • Cary Claiborne was promoted to President and Chief Executive Officer of Adial from his previous role as Chief Operating Officer.
  • Mr. Claiborne was appointed Chief Operating Officer of Adial in December 2021 after previously being named to the Board of Directors.

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

Retrieved on: 
Tuesday, September 20, 2022
Sucampo Pharmaceuticals, Lists of diseases, SCMP, Director, Glycogen storage disease, Â, Sumathi Best Television Current Reporting Award, Company, Growth, MJFF, Private Securities Litigation Reform Act, Cooley, Therapy, Forward-looking statement, Biozentrum University of Basel, Cooley LLP, U.S. Securities and Exchange Commission, Risk, CEO, Protein, Goal, Nasdaq, Novartis, Board of directors, The Michael J. Fox Foundation, Board, Security (finance), GLOBE, Gaucher's disease, University, Drug discovery, Michael J. Astrue, GBA, Pharmaceutical industry

BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, the Companys current Chief Operating Officer, has been appointed as the Companys Chief Executive Officer, effective immediately.

Key Points: 
  • BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (Gain, or the Company), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, the Companys current Chief Operating Officer, has been appointed as the Companys Chief Executive Officer, effective immediately.
  • I am excited to be transitioning into the role of CEO and leading Gain in our next phase of growth, said Matthias Alder.
  • Since joining Gain as Chief Operating Officer in 2021, Mr. Alder has been instrumental in building the Companys corporate and business development strategy and shaping the Companys operations.Mr.
  • Prior to joining Gain, he served as Chief Business Officer and Head of US Operations of Autolus Therapeutics (Nasdaq: AUTL).

Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs

Retrieved on: 
Wednesday, September 7, 2022
AstraZeneca, Technology, Science, U.S. Securities and Exchange Commission, Harvard University, GLOBE, Leadership, Biology, Company, Broad Institute, Lists of diseases, Patient, B.A, Salk Institute for Biological Studies, Corporate Affairs, Genetics, Government, Sale, SVP, MIT, Private Securities Litigation Reform Act, Senior, Texas A&M University, CSO, CFO, Nasdaq, FDA, Rutgers University, Rider University, Johnson & Johnson, Industry, Morrison, AAV, Frequency, PR, Security (finance), Corporation, Therapy, Spinal muscular atrophy, LLP, R, Tulane University, Public relations, MBA, Drug development, Marketing, Ernst & Young, Columbia University, Biomedical Research, Communication, Publication, Annual report, CNS, Management, Pharmaceutical industry, Voyager, Sucampo Pharmaceuticals, Research, Intention, Mallinckrodt

Petes extensive corporate finance experience will be integral in maximizing the value of our AAV capsid platform and our pipeline.

Key Points: 
  • Petes extensive corporate finance experience will be integral in maximizing the value of our AAV capsid platform and our pipeline.
  • Peter Pfreundschuh hasmore than 25 years of finance, business development, commercial and public company leadership experience in the life sciences and medical device industries.
  • Trista Morrison has more than 20 years of experience in healthcare public affairs, including strategic communications, investor relations and patient advocacy.
  • Pfreundschuh, Carter and Morrison will report to Voyager CEO Al Sandrock, M.D., Ph.D., and will serve on Voyagers Senior Leadership Team.

Adial Pharmaceuticals Names Cary Claiborne as Chief Executive Officer

Retrieved on: 
Monday, August 22, 2022
Amyotrophic lateral sclerosis, National Association, CEO, Pain, Research, Stilley, Addiction, Adenosine, Maintenance, U.S. Securities and Exchange Commission, GLOBE, Leadership, Company, Sucampo Pharmaceuticals, M.B.A, Patient, Inflammation, EMA, Telephone, Cancer, Obesity, Business administration, Time, CytRx, Sale, Fatty liver disease, Board, EDT, CFO, FDA, Rutgers University, Communication, Diabetes, Director, Partnership, Security (finance), Corporation, Therapy, NASDAQ, Villanova University, AUD, Vice, Drinking, Gambling, Growth, Health, National Association of Corporate Directors, Marketing, Nature, NACD, Asthma, Infection, NASH, Annual report, Eye, Perfume, Pharmaceutical industry, Indivior, Nasdaq, Mallinckrodt

CHARLOTTESVILLE, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the appointment of Cary J. Claiborne as President and Chief Executive Officer. Mr. Claiborne, who has 18 years of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies, takes over the role of William Stilley, who was appointed to the newly created position of CEO of Purnovate, Inc. Both executives will remain on the Board of Directors of Adial. The Company also announced that Kevin Schuyler, who has served as Vice Chairman and as an independent director, has been appointed Chairman.

Key Points: 
  • Mr. Claiborne was appointed Chief Operating Officer of Adial in December 2022 after previously being named to the Board of Directors.
  • Most recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses.
  • Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt.
  • As CEO, Cary brings extensive experience as an executive and board member with other commercial stage biopharma businesses.

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

Retrieved on: 
Tuesday, June 14, 2022
Retina, Walden University, Eye, Pharming, Annual report, Axitinib, Drug, Senior, Texas Wesleyan University, University, U.S. Securities and Exchange Commission, University of North Texas, GLOBE, Patient, Private Securities Litigation Reform Act, Choroid, COVID-19, Bausch & Lomb, NASDAQ, SEC, Concluding observations on the second periodic report of the Holy See, Alcon, Sucampo Pharmaceuticals, SCS, Pharmaceutical industry, Public health, Epidemiology, Biology, Clearside

We are very excited to have Susan join our team, said George Lasezkay, Pharm.D., J.D., Clearsides President and Chief Executive Officer.

Key Points: 
  • We are very excited to have Susan join our team, said George Lasezkay, Pharm.D., J.D., Clearsides President and Chief Executive Officer.
  • With her broad experience in clinical development at multiple leading ophthalmic companies, she will make significant contributions to Clearsides vision, strategy, and operational effectiveness.
  • Dr. Thomas Ciulla, our Chief Medical Officer and Chief Development Officer, will continue his current responsibilities for clinical trial design and overall product pipeline strategy and development.
  • Tom will work closely with Susan regarding the implementation and analysis of our clinical pipeline programs.

Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Information technology, NACD, Company, Opioid use disorder, Research, GLOBE, Addiction, Growth, Security (finance), Adenosine, Pain, Inflammation, Villanova University, National Association, Obesity, Board of directors, Patient, Therapy, Corporation, Gambling, Director, Nature, Cancer, Diabetes, Business administration, Treasury, Asthma, Board, National Association of Corporate Directors, AUD, Maintenance, Cocaine, Time, Sucampo Pharmaceuticals, Drinking, NASDAQ, Marketing, Sale, Infection, Annual report, CFO, Rutgers University, Communication, Pharmaceutical industry

William Stilley, Adials Chief Executive Officer, stated, We are honored to welcome Cary to the senior management team as Chief Operating Officer, following his recent appointment to our Board of Directors.

Key Points: 
  • William Stilley, Adials Chief Executive Officer, stated, We are honored to welcome Cary to the senior management team as Chief Operating Officer, following his recent appointment to our Board of Directors.
  • We look forward to Cary executing in his new role as we pursue potential strategic and partnering activities around our growing pipeline.
  • Mr. Truluck added, Cary joins our senior management team at the beginning of a new stage in the growth of Adial.
  • Mr. Claiborne previously served as Chief Financial Officer (CFO) and board member of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses.